ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 139,28
-0,69%
Dow Jones
39 872,11
0,16%
DAX
18 726,08
-0,22%
Brent Oil
83,06
-0,56%
Bitcoin
70 322,74
-1,57%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Bright Minds Biosciences Inc (DRUG)

  7. Bright Minds Biosciences Inc (DRUG) Actualités

DRUG

Bright Minds Biosciences (DRUG)

Bright Minds Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DRUG
DateHeureSourceTitreSymboleSociété
27/02/202402h18Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:DRUGBright Minds Biosciences Inc
13/02/202403h56Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:DRUGBright Minds Biosciences Inc
18/01/202418h57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:DRUGBright Minds Biosciences Inc
29/12/202322h30Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:DRUGBright Minds Biosciences Inc
06/12/202323h08PR Newswire (Canada)Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by ManagementNASDAQ:DRUGBright Minds Biosciences Inc
08/08/202312h50GlobeNewswire Inc.Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101NASDAQ:DRUGBright Minds Biosciences Inc
20/07/202312h50GlobeNewswire Inc.Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101NASDAQ:DRUGBright Minds Biosciences Inc
11/07/202312h50GlobeNewswire Inc.Bright Minds Announces Effective Date of Share ConsolidationNASDAQ:DRUGBright Minds Biosciences Inc
22/06/202321h37Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:DRUGBright Minds Biosciences Inc
22/06/202312h50GlobeNewswire Inc.Bright Minds Announces Proposed Share ConsolidationNASDAQ:DRUGBright Minds Biosciences Inc
19/04/202312h50GlobeNewswire Inc.Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202NASDAQ:DRUGBright Minds Biosciences Inc
10/04/202312h50GlobeNewswire Inc.Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin ResearchNASDAQ:DRUGBright Minds Biosciences Inc
27/02/202312h50GlobeNewswire Inc.Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023NASDAQ:DRUGBright Minds Biosciences Inc
17/02/202312h50GlobeNewswire Inc.Bright Minds Biosciences Announces Non-Executive Director AppointmentNASDAQ:DRUGBright Minds Biosciences Inc
08/02/202322h05GlobeNewswire Inc.Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee RequirementsNASDAQ:DRUGBright Minds Biosciences Inc
27/01/202322h05GlobeNewswire Inc.Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:DRUGBright Minds Biosciences Inc
09/01/202322h05GlobeNewswire Inc.Bright Minds Biosciences Announces Resignation of Board MemberNASDAQ:DRUGBright Minds Biosciences Inc
03/12/202201h06GlobeNewswire Inc.Bright Minds Biosciences Announces Closing of Non-Brokered Private PlacementNASDAQ:DRUGBright Minds Biosciences Inc
28/11/202212h50GlobeNewswire Inc.Bright Minds Biosciences Announces Non-Brokered Private PlacementNASDAQ:DRUGBright Minds Biosciences Inc
23/11/202217h35GlobeNewswire Inc.Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical OfficerNASDAQ:DRUGBright Minds Biosciences Inc
14/09/202223h29Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:DRUGBright Minds Biosciences Inc
07/09/202212h50GlobeNewswire Inc.Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of DirectorsNASDAQ:DRUGBright Minds Biosciences Inc
31/08/202212h50GlobeNewswire Inc.Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet SyndromeNASDAQ:DRUGBright Minds Biosciences Inc
30/08/202221h35GlobeNewswire Inc.Bright Minds Biosciences Announces Closing of $4 Million Unit OfferingNASDAQ:DRUGBright Minds Biosciences Inc
24/08/202203h06GlobeNewswire Inc.Bright Minds Announces Pricing of Overnight Marketed Offering of UnitsNASDAQ:DRUGBright Minds Biosciences Inc
18/08/202221h33GlobeNewswire Inc.Bright Minds Biosciences Comments on Recent Trading ActivityNASDAQ:DRUGBright Minds Biosciences Inc
27/06/202212h50GlobeNewswire Inc.Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development OrganizationNASDAQ:DRUGBright Minds Biosciences Inc
12/05/202212h50GlobeNewswire Inc.Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet SyndromeNASDAQ:DRUGBright Minds Biosciences Inc
02/05/202212h50GlobeNewswire Inc.Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health SpecialtiesNASDAQ:DRUGBright Minds Biosciences Inc
19/04/202212h50GlobeNewswire Inc.Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion LeadersNASDAQ:DRUGBright Minds Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:DRUG

Dernières Valeurs Consultées

NYSE
TALO.WS
Talos Energy
COIN
RINGUSD
Darwinia Network Native Token
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés